April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Subjective Perception And Objective Parameters Of Visual Function After Intravitreal Ranibizumab Treatment
Author Affiliations & Notes
  • Konrad R. Koch
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Philipp S. Muether
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Manuel M. Hermann
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Robert Hoerster
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Bernd Kirchhof
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Sascha Fauser
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships  Konrad R. Koch, None; Philipp S. Muether, None; Manuel M. Hermann, None; Robert Hoerster, None; Bernd Kirchhof, None; Sascha Fauser, None
  • Footnotes
    Support  Supported by the Koeln Fortune Program / Faculty of Medicine, University of Cologne
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1662. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Konrad R. Koch, Philipp S. Muether, Manuel M. Hermann, Robert Hoerster, Bernd Kirchhof, Sascha Fauser; Subjective Perception And Objective Parameters Of Visual Function After Intravitreal Ranibizumab Treatment. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1662.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To investigate the relation between subjective perception of visual function and changes of objective parameters after intravitreal ranibizumab treatment in patients suffering from exsudative AMD.

 
Methods:
 

In a prospective interventional case series, 74 eyes of 74 patients with exsudative AMD received an initial treatment series of 3 intravitreal ranibizumab injections (IVI) within 3 months follow-up. Standardized monthly patient interviews assessed patients’ subjective perception including whether visual quality of the study eye either improved, worsened or remained stable over the observed time course. Objective parameters measured at baseline and 3 months included BCVA (using ETDRS), reading acuity (RA, using LogRAD), and OCT central thickness (height from choroid), and changes were tested for statistical significance with Pearson's chi-square and Mann-Whitney U tests where applicable.

 
Results:
 

50 out of 74 patients (68%) perceived a subjective improvement, 16 patients (21%) no subjective change, and 8 patients (11%) a subjective worsening of visual function. According changes of objective parameters (3 months minus baseline) for these three groups are shown in the table below. These findings were independent of whether the better or worse eye (based on BCVA at baseline) was treated (p> 0.9).

 
Conclusions:
 

In our study 2/3 of patients subjectively benefited from the intravitreal ranibizumab treatment. Subjective perception was significantly correlated with objective changes. Our data indicate that the mean threshold for subjective improvement perception after IVI for AMD is an increase by two to six ETDRS letters.Our data demonstrate that patients have the same sensitivity for improvement or deterioration when their worse eye is treated.  

 
Keywords: age-related macular degeneration • vascular endothelial growth factor • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×